Novo Nordisk ASMEX:NOVOBN +3.85%79 Net Margin % is 50.15% as of Mar. 2026, which is 48% above its 10-year median of 33.93. GuruFocus rates MEX:NOVOBN with a GF Score™ of 79/100 and a GF Value™ of MXN2,387.36 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 956 Drug Manufacturers companies, Novo Nordisk AS ranks better than 96.65% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Novo Nordisk AS's Net Income for the
three
months ended in Mar. 2026 was MXN135,433 Mil. Novo Nordisk AS's Revenue for the
three
months ended in Mar. 2026 was MXN270,054 Mil. Therefore, Novo Nordisk AS's net margin for the quarter that ended in Mar. 2026 was 50.15%.
The historical rank and industry rank for Novo Nordisk AS's Net Margin % or its related term are showing as below:
MEX:NOVOBN'
s Net Margin % Range Over the Past 10 Years
Min: 31.38 Med: 33.93 Max: 37.21
Current: 37.21
MEX:NOVOBN's Net Margin % is ranked better than 96.65% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs MEX:NOVOBN: 37.21
Novo Nordisk AS (MEX:NOVOBN) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Novo Nordisk AS Net Margin % Related Terms
Novo Nordisk AS Net Margin % Historical Data
* Premium members only.
The historical data trend for Novo Nordisk AS's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:NOVOBN vs LLY, JNJ, ABBV: Net Margin % Comparison
For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novo Nordisk AS Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Net Margin % distribution charts can be found below:
* The bar in red indicates where Novo Nordisk AS's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novo Nordisk AS (MEX:NOVOBN) has a Net Margin % of 50.15% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Novo Nordisk AS and its competitors. This is 48% above median its historical median of 33.93. Over the past decade, Novo Nordisk AS's Net Margin % has ranged from 31.38 to 37.21. According to the industry distribution chart, Novo Nordisk AS ranks #32 out of 956 companies in the Drug Manufacturers industry, placing it in the top 3.3%.
Is Novo Nordisk AS's Net Margin % too high?
Novo Nordisk AS's current Net Margin % of 50.15% is 48% above median its 10-year median of 33.93. Over the past 10 years, this metric has ranged from a low of 31.38 to a high of 37.21. The Drug Manufacturers industry median Net Margin % is 5.56. Novo Nordisk AS's value of 50.15% is 802% above this industry median. Based on the distribution chart, Novo Nordisk AS ranks #32 out of 956 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Novo Nordisk AS has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's Net Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Novo Nordisk AS ranks #32 out of 956 companies for Net Margin %. This places Novo Nordisk AS in the top 3% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.56. Novo Nordisk AS's value of 50.15% is 802% above this benchmark. Historically, Novo Nordisk AS's own Net Margin % has ranged from 31.38 to 37.21 over the past decade. While the company's 10-year median is 33.93 vs. the industry median of 5.56, Novo Nordisk AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novo Nordisk AS's current Net Margin % of 50.15% is 802% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Novo Nordisk AS and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novo Nordisk AS's current Net Margin % is 50.15%, which is 48% above median its own 10-year median of 33.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (MEX:NOVOBN) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN2,387.36, compared to a current price of MXN810.00 — trading 66.1% below its estimated fair value. The current Net Margin % is 50.15%, which is 48% above median its 10-year median of 33.93 and 802% above the Drug Manufacturers industry median of 5.56. Novo Nordisk AS's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Novo Nordisk AS (MEX:NOVOBN), the current Net Margin % is 50.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novo Nordisk AS (MEX:NOVOBN) Overvalued in 2026?
Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued.
The current stock price of MXN810.00 is trading 66.1% below its estimated GF Value™ of MXN2,387.36.
GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.
Key valuation signals for MEX:NOVOBN:
Net Margin %: 50.15% (48% above median its 10-year median of 33.93)
GF Value™: MXN2,387.36 vs. price of MXN810.00 (66.1% below fair value)
Industry Position: 802% above the Drug Manufacturers median (#32 of 956)
No single metric tells the full story. See the MEX:NOVOBN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
79GF Score
Get the complete analysis for MEX:NOVOBN
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NOVOBN has been successfully added to your 
